Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CTI Biopharma

- PMLiVE

Rare cancer specialists Sierra Oncology acquired by GSK for £1.5bn

Unification will help to uphold and progress promising Momelotinib treatment which targets myelofibrosis

- PMLiVE

AstraZeneca blocks take-private buyout of Sobi

The $7.6bn takeover of Swedish rare disease company Sobi by private equity group Advent International and Singapore’s wealth fund failed to convince the 90% of shareholders needed

- PMLiVE

Sobi’s Gamifant receives final rejection from CHMP for primary HLH

Committee reiterated previous negative opinion

Roche Basel Switzerland

Roche agrees $1.4bn takeover of fibrosis specialist Promedior

Portfolio includes phase 2 candidate with FDA breakthrough status

- PMLiVE

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Hopes to boost haematology franchise with lead drug Doptelet

AstraZeneca AZ

AstraZeneca buys FDA priority review voucher from Sobi

Picks up coveted voucher for $95m

Celgene building

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Currently in the middle of merger

- PMLiVE

Sobi takes ownership of rare disease drug Gamifant for $518m

Fulfils rare disease firm's global expansion plans

- PMLiVE

Sobi shows strong growth despite haemophilia competition

Looking to M&A for continued growth

- PMLiVE

FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease

Approval adds to growing US portfolio

- PMLiVE

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ continues sell-off, SOBI spies US expansion

- PMLiVE

BMS appoints new commercial leader, Davies joins Eisai and more

The latest industry movers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links